Background: Molecular testing in advanced lung cancer is standard in guiding treatment selection. However, population‐wide implementation of testing remains a challenge. We developed a knowledge translation intervention to improve understanding among diagnostic specialists about molecular testing and appropriate diagnostic sampling in lung cancer. Methods: Specialty‐specific education programs were developed from existing literature and input from Canadian leaders in lung pathology, respirology, interventional radiology, thoracic surgery, radiation oncology, and medical oncology. The programs, including key messages, review of current data, existing guidelines, group discussion, and participant feedback, were administered at provincial and national specialty meetings. Participant knowledge was assessed before and after the intervention by using anonymous questionnaires. Molecular (EGFR) testing rates in Ontario were also evaluated before and after the intervention period. Results: Ten programs were administered to diagnostic specialists, including respirologists, pathologists, thoracic surgeons, radiologists, radiation oncologists, and medical oncologists, with completion of 255 preintervention and 219 postintervention surveys. At baseline, 30% were unsure of tissue handling methods for molecular testing, 20% chose an incorrect technique, and half were unfamiliar with how to initiate testing. After intervention, specialist knowledge improved regarding tissue handling and appropriate fixation techniques and uncertainty decreased from 30% to 2% (p < 0.001). A 12% increase (relative increase 57%) in molecular (EGFR) testing requests in Ontario was observed over the intervention period (p = 0.0032). Conclusions: Significant knowledge gaps exist among diagnostic specialists regarding molecular testing and targeted therapy in lung cancer. This initiative significantly improved understanding of the importance and methods of successful molecular testing and correlated with increased testing rates.

中文翻译：

---

将知识转化为实践 - 提高对 NSCLC 分子检测的认识

背景：晚期肺癌的分子检测是指导治疗选择的标准。然而，在全人群范围内实施检测仍然是一个挑战。我们开发了一种知识翻译干预措施，以提高诊断专家对肺癌分子检测和适当诊断采样的理解。方法：根据现有文献和加拿大肺病理学、呼吸学、介入放射学、胸外科、放射肿瘤学和医学肿瘤学领域的领导者的意见制定了专门的教育计划。这些项目，包括关键信息、当前数据审查、现有指南、小组讨论和参与者反馈，在省和国家专业会议上进行管理。参与者的知识在干预前后通过匿名问卷进行评估。安大略省的分子 (EGFR) 检测率也在干预期前后进行了评估。结果：对诊断专家实施了 10 项计划，包括呼吸科医师、病理学家、胸外科医生、放射科医师、放射肿瘤学家和医学肿瘤学家，完成了 255 项干预前调查和 219 项干预后调查。在基线时，30% 的人不确定用于分子检测的组织处理方法，20% 的人选择了不正确的技术，还有一半人不熟悉如何开始检测。干预后，关于组织处理和适当固定技术的专业知识得到改善，不确定性从 30% 降低到 2% (p < 0.001)。在干预期间，安大略省的分子 (EGFR) 检测请求增加了 12%（相对增加了 57%）（p = 0.0032）。结论：诊断专家在肺癌分子检测和靶向治疗方面存在重大知识差距。这一举措显着提高了对成功分子检测的重要性和方法的理解，并与提高检测率相关。